Glenmark Pharmaceuticals receives US FDA EIR with VAI status for Monroe facility
Glenmark Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US FDA for its Monroe, North Carolina formulations facility, classified as Voluntary Action Indicated (VAI). The positive outcome clears the way for resumption of commercial manufacturing.
By Finblage Editorial Desk
11:00 am
27 November 2025
Sources & Disclaimer
This article is compiled from publicly available information, including company disclosures, stock exchange filings, regulatory announcements, and reports from global and domestic financial publications. The content has been editorially reviewed and enhanced by the Finblage Editorial Desk for clarity and investor awareness purposes only.
All information provided on Finblage is strictly for educational and informational use and should not be considered as financial, investment, legal, or professional advice. Readers are advised to conduct their own independent research and consult a certified financial advisor before making any investment decisions. Finblage shall not be held responsible for any losses arising from the use of information published on this website.
_edited.png)





